Herpes labialis of the lower lip. Note the blisters in a group marked by an arrow.
|Classification and external resources|
|ICD-10||A60, B00, G05.1, P35.2|
|ICD-9-CM||054.0, 054.1, 054.2, 054.3, 771.2|
Herpes simplex (Greek: ἕρπης herpēs, "creeping" or "latent") is a viral disease caused by the herpes simplex virus. Infections are categorized based on the part of the body infected. Oral herpes involves the face or mouth. It may result in small blisters in groups often called cold sores or fever blisters or may just cause a sore throat. Genital herpes, often simply known as herpes, may have minimal symptoms or form blisters that break open and result in small ulcers. These typically heal over two to four weeks. Tingling or shooting pains may occur before the blisters appear. Herpes cycles between periods of active disease followed by periods without symptoms. The first episode is often more severe and may be associated with fever, muscle pains, swollen lymph nodes and headaches. Over time, episodes of active disease decrease in frequency and severity. Other disorders caused by herpes simplex include: herpetic whitlow when it involves the fingers, herpes of the eye, herpes infection of the brain, and neonatal herpes when it affects a newborn, among others.
There are two types of herpes simplex virus, type 1 (HSV-1) and type 2 (HSV-2). HSV-1 more commonly causes oral infections while HSV-2 more commonly causes genital infections. They are transmitted by direct contact with body fluids or lesions of an infected individual. Transmission may still occur when symptoms are not present. Genital herpes is classified as a sexually transmitted infection. It may be spread to an infant during childbirth. After infection, the viruses are transported along sensory nerves to the nerve cell bodies, where they reside lifelong. Causes of recurrence may include: decreased immune function, stress, and sunlight exposure. Oral and genital herpes is usually diagnosed based on the presenting symptoms. The diagnosis may be confirmed by viral culture or detecting herpes DNA in fluid from blisters. Testing the blood for antibodies against the virus can confirm a previous infection but will be negative in new infections.
The most effective method of avoiding genital infections is by avoiding vaginal, oral and anal sex. Condom use decreases the risk somewhat. Daily antiviral medication taken by someone who has the infection can also reduce spread. There is no available vaccine and once infected, there is no cure. Paracetamol (acetaminophen) and topical lidocaine may be used to help with the symptoms. Treatments with antiviral medication such as aciclovir or valaciclovir can lessen the severity of symptomatic episodes.
Worldwide rates of either HSV-1 or HSV-2 are between 60% and 95% in adults. HSV-1 is usually acquired during childhood. Rates of both increase as people age. Rates of HSV-1 are between 70% and 80% in populations of low socioeconomic status and 40% to 60% in populations of improved socioeconomic status. An estimated 536 million people worldwide (16% of the population) were infected with HSV-2 as of 2003 with greater rates among women and those in the developing world. Most people with HSV-2 do not realize that they are infected.
- 1 Classification
- 2 Signs and symptoms
- 3 Pathophysiology
- 4 Diagnosis
- 5 Prevention
- 6 Management
- 7 Prognosis
- 8 Epidemiology
- 9 History
- 10 Society and culture
- 11 Research
- 12 References
- 13 External links
Herpes simplex is divided into two types; HSV-1 causes primarily mouth, throat, face, eye, and central nervous system infections, whereas HSV-2 causes primarily anogenital infections. However, each may cause infections in all areas.
Signs and symptoms
HSV infection causes several distinct medical disorders. Common infection of the skin or mucosa may affect the face and mouth (orofacial herpes), genitalia (genital herpes), or hands (herpetic whitlow). More serious disorders occur when the virus infects and damages the eye (herpes keratitis), or invades the central nervous system, damaging the brain (herpes encephalitis). People with immature or suppressed immune systems, such as newborns, transplant recipients, or people with AIDS, are prone to severe complications from HSV infections. HSV infection has also been associated with cognitive deficits of bipolar disorder, and Alzheimer's disease, although this is often dependent on the genetics of the infected person.
In all cases, HSV is never removed from the body by the immune system. Following a primary infection, the virus enters the nerves at the site of primary infection, migrates to the cell body of the neuron, and becomes latent in the ganglion. As a result of primary infection, the body produces antibodies to the particular type of HSV involved, preventing a subsequent infection of that type at a different site. In HSV-1-infected individuals, seroconversion after an oral infection prevents additional HSV-1 infections such as whitlow, genital herpes, and herpes of the eye. Prior HSV-1 seroconversion seems to reduce the symptoms of a later HSV-2 infection, although HSV-2 can still be contracted.
|Herpetic gingivostomatitis||Herpetic gingivostomatitis is often the initial presentation during the first herpes infection. It is of greater severity than herpes labialis, which is often the subsequent presentations.|
|Herpes labialis||Infection occurs when the virus comes into contact with oral mucosa or abraded skin.|
|Herpes genitalis||When symptomatic, the typical manifestation of a primary HSV-1 or HSV-2 genital infection is clusters of inflamed papules and vesicles on the outer surface of the genitals resembling cold sores.|
|Herpetic whitlow and herpes gladiatorum||Herpes whitlow is a painful infection that typically affects the fingers or thumbs. On occasion, infection occurs on the toes or on the nail cuticle. Individuals who participate in contact sports such as wrestling, rugby, and football(soccer), sometimes acquire a condition caused by HSV-1 known as herpes gladiatorum, scrumpox, wrestler's herpes, or mat herpes, which presents as skin ulceration on the face, ears, and neck. Symptoms include fever, headache, sore throat, and swollen glands. It occasionally affects the eyes or eyelids.|
|Herpesviral encephalitis and herpesviral meningitis||A herpetic infection of the brain thought to be caused by the retrograde transmission of virus from a peripheral site on the face following HSV-1 reactivation, along the trigeminal nerve axon, to the brain. HSV is the most common cause of viral encephalitis. When infecting the brain, the virus shows a preference for the temporal lobe. HSV-2 is the most common cause of Mollaret's meningitis, a type of recurrent viral meningitis.|
|Herpes esophagitis||Symptoms may include painful swallowing (odynophagia) and difficulty swallowing (dysphagia). It is often associated with impaired immune function (e.g. HIV/AIDS, immunosuppression in solid organ transplants).|
Neonatal herpes simplex is a HSV infection in an infant. It is a rare but serious condition, usually caused by vertical transmission of HSV-1 or -2) from mother to newborn. During immunodeficiency, herpes simplex can cause unusual lesions in the skin. One of the most striking is the appearance of clean linear erosions in skin creases, with the appearance of a knife cut. Herpetic sycosis is a recurrent or initial herpes simplex infection affecting primarily the hair follicles.:369 Eczema herpeticum is an infection with herpesvirus in patients with chronic atopic dermatitis may result in spread of herpes simples throughout the eczematous areas.:373
Herpetic keratoconjunctivitis, a primary infection, typically presents as swelling of the conjunctiva and eyelids (blepharoconjunctivitis), accompanied by small white itchy lesions on the surface of the cornea.
Although the exact cause of Bell's palsy—a type of facial paralysis—is unknown, it may be related to reactivation of HSV-1. This theory has been contested, however, since HSV is detected in large numbers of individuals having never experienced facial paralysis, and higher levels of antibodies for HSV are not found in HSV-infected individuals with Bell's palsy compared to those without. Regardless antivirals have been found to not improve outcomes.
HSV-1 has been proposed as a possible cause of Alzheimer's disease. In the presence of a certain gene variation (APOE-epsilon4 allele carriers), HSV-1 appears to be particularly damaging to the nervous system and increases one's risk of developing Alzheimer's disease. The virus interacts with the components and receptors of lipoproteins, which may lead to its development.
|HSV-2 genital||15–25% of days|
|HSV-1 oral||6–33% of days|
|HSV-1 genital||5% of days|
|HSV-2 oral||1% of days|
Herpes is contracted through direct contact with an active lesion or body fluid of an infected person. Herpes transmission occurs between discordant partners; a person with a history of infection (HSV seropositive) can pass the virus to an HSV seronegative person. Herpes simplex virus 2 is typically contracted through direct skin-to-skin contact with an infected individual, but can also be contacted by exposure to infected saliva, semen, vaginal fluid, or the fluid from herpetic blisters. To infect a new individual, HSV travels through tiny breaks in the skin or mucous membranes in the mouth or genital areas. Even microscopic abrasions on mucous membranes are sufficient to allow viral entry.
HSV asymptomatic shedding occurs at some time in most individuals infected with herpes. It can occur more than a week before or after a symptomatic recurrence in 50% of cases. Virus enters into susceptible cells by entry receptors such as nectin-1, HVEM and 3-O sulfated heparan sulfate. Infected people who show no visible symptoms may still shed and transmit viruses through their skin; asymptomatic shedding may represent the most common form of HSV-2 transmission. Asymptomatic shedding is more frequent within the first 12 months of acquiring HSV. Concurrent infection with HIV increases the frequency and duration of asymptomatic shedding. Some individuals may have much lower patterns of shedding, but evidence supporting this is not fully verified; no significant differences are seen in the frequency of asymptomatic shedding when comparing persons with one to 12 annual recurrences to those with no recurrences.
Antibodies that develop following an initial infection with a type of HSV prevents reinfection with the same virus type—a person with a history of orofacial infection caused by HSV-1 cannot contract herpes whitlow or a genital infection caused by HSV-1. In a monogamous couple, a seronegative female runs a greater than 30% per year risk of contracting an HSV infection from a seropositive male partner. If an oral HSV-1 infection is contracted first, seroconversion will have occurred after 6 weeks to provide protective antibodies against a future genital HSV-1 infection. Herpes simplex is a double-stranded DNA virus.
Primary orofacial herpes is readily identified by clinical examination of persons with no previous history of lesions and contact with an individual with known HSV-1 infection. The appearance and distribution of sores in these individuals typically presents as multiple, round, superficial oral ulcers, accompanied by acute gingivitis. Adults with atypical presentation are more difficult to diagnose. Prodromal symptoms that occur before the appearance of herpetic lesions help differentiate HSV symptoms from the similar symptoms of other disorders, such as allergic stomatitis. When lesions do not appear inside the mouth, primary orofacial herpes is sometimes mistaken for impetigo, a bacterial infection. Common mouth ulcers (aphthous ulcer) also resemble intraoral herpes, but do not present a vesicular stage.
Genital herpes can be more difficult to diagnose than oral herpes, since most HSV-2-infected persons have no classical symptoms. Further confusing diagnosis, several other conditions resemble genital herpes, including fungal infection, lichen planus, atopic dermatitis, and urethritis. Laboratory testing is often used to confirm a diagnosis of genital herpes. Laboratory tests include culture of the virus, direct fluorescent antibody (DFA) studies to detect virus, skin biopsy, and polymerase chain reaction to test for presence of viral DNA. Although these procedures produce highly sensitive and specific diagnoses, their high costs and time constraints discourage their regular use in clinical practice.
Until recently, serological tests for antibodies to HSV were rarely useful to diagnosis and not routinely used in clinical practice. The older IgM serologic assay could not differentiate between antibodies generated in response to HSV-1 or HSV-2 infection. However, the new Immunodot glycoprotein G-specific (IgG) HSV test is more than 98% specific at discriminating HSV-1 from HSV-2. Some believe the new IgG test should always be preferred to the old IgM test.
It should not be confused with conditions caused by other viruses in the herpesviridae family such as herpes zoster, which is caused by varicella zoster virus. The differential diagnosis includes hand, foot and mouth disease due to similar lesions on the skin.
As with almost all sexually transmitted infections, women are more susceptible to acquiring genital HSV-2 than men. On an annual basis, without the use of antivirals or condoms, the transmission risk of HSV-2 from infected male to female is about 8–11%. This is believed to be due to the increased exposure of mucosal tissue to potential infection sites. Transmission risk from infected female to male is around 4–5% annually. Suppressive antiviral therapy reduces these risks by 50%. Antivirals also help prevent the development of symptomatic HSV in infection scenarios, meaning the infected partner will be seropositive but symptom-free by about 50%. Condom use also reduces the transmission risk significantly. Condom use is much more effective at preventing male-to-female transmission than vice versa. Previous HSV-1 infection appears to reduce the risk for acquisition of HSV-2 infection among women by a factor of three.
However, asymptomatic carriers of the HSV-2 virus are still contagious. In many infections, the first symptom people will have of their own infections is the horizontal transmission to a sexual partner or the vertical transmission of neonatal herpes to a newborn at term. Since most asymptomatic individuals are unaware of their infection, they are considered at high risk for spreading HSV.
Condoms offer moderate protection against HSV-2 in both men and women, with consistent condom users having a 30%-lower risk of HSV-2 acquisition compared with those who never use condoms. A female condom can provide greater protection than the male condom, as it covers the labia. The virus cannot pass through a synthetic condom, but a male condom's effectiveness is limited because herpes ulcers may appear on areas not covered by it. Neither type of condom prevents contact with the scrotum, anus, buttocks, or upper thighs, areas that may come in contact with ulcers or genital secretions during sexual activity. Protection against herpes simplex depends on the site of the ulcer; therefore, if ulcers appear on areas not covered by condoms, abstaining from sexual activity until the ulcers are fully healed is one way to limit risk of transmission. The risk is not eliminated, however, as viral shedding capable of transmitting infection may still occur while the infected partner is asymptomatic. The use of condoms or dental dams also limits the transmission of herpes from the genitals of one partner to the mouth of the other (or vice versa) during oral sex. When one partner has a herpes simplex infection and the other does not, the use of antiviral medication, such as valaciclovir, in conjunction with a condom, further decreases the chances of transmission to the uninfected partner. Topical microbicides that contain chemicals that directly inactivate the virus and block viral entry are being investigated.
Antivirals may reduce asymptomatic shedding; asymptomatic genital HSV-2 viral shedding is believed to occur on 20% of days per year in patients not undergoing antiviral treatment, versus 10% of days while on antiviral therapy.
The risk of transmission from mother to baby is highest if the mother becomes infected around the time of delivery (30% to 60%), since insufficient time will have occurred for the generation and transfer of protective maternal antibodies before the birth of the child. In contrast, the risk falls to 3% if the infection is recurrent, and is 1–3% if the woman is seropositive for both HSV-1 and HSV-2, and is less than 1% if no lesions are visible. Women seropositive for only one type of HSV are only half as likely to transmit HSV as infected seronegative mothers. To prevent neonatal infections, seronegative women are recommended to avoid unprotected oral-genital contact with an HSV-1-seropositive partner and conventional sex with a partner having a genital infection during the last trimester of pregnancy. Mothers infected with HSV are advised to avoid procedures that would cause trauma to the infant during birth (e.g. fetal scalp electrodes, forceps, and vacuum extractors) and, should lesions be present, to elect caesarean section to reduce exposure of the child to infected secretions in the birth canal. The use of antiviral treatments, such as acyclovir, given from the 36th week of pregnancy, limits HSV recurrence and shedding during childbirth, thereby reducing the need for caesarean section.
Acyclovir is the recommended antiviral for herpes suppressive therapy during the last months of pregnancy. The use of valaciclovir and famciclovir, while potentially improving compliance, have less-well-determined safety in pregnancy.
No method eradicates herpes virus from the body, but antiviral medications can reduce the frequency, duration, and severity of outbreaks. Analgesics such as ibuprofen and paracetamol (acetaminophen) can reduce pain and fever. Topical anesthetic treatments such as prilocaine, lidocaine, benzocaine, or tetracaine can also relieve itching and pain.
Several antiviral drugs are effective for treating herpes, including acyclovir, valaciclovir (valacyclovir), famciclovir, and penciclovir. Acyclovir was the first discovered and is now available in generic. Valacyclovir is also available as a generic.
Evidence supports the use of acyclovir and valacyclovir in the treatment of herpes labialis as well as herpes infections in people with cancer. The evidence to support the use of acyclovir in primary herpetic gingivostomatitis is weaker.
Certain dietary supplements and alternative remedies are claimed to be beneficial in the treatment of herpes. Evidence is insufficient, though, to support use of many of these compounds, including echinacea, eleuthero, L-lysine, zinc, monolaurin bee products, and aloe vera. While a number of small studies show possible benefit from monolaurin, L-lysine, aspirin, lemon balm, topical zinc, or licorice root cream in treatment, these preliminary studies have not been confirmed by higher-quality randomized controlled studies.
Following active infection, herpes viruses establish a latent infection in sensory and autonomic ganglia of the nervous system. The double-stranded DNA of the virus is incorporated into the cell physiology by infection of the nucleus of a nerve's cell body. HSV latency is static; no virus is produced; and is controlled by a number of viral genes, including latency-associated transcript.
Many HSV-infected people experience recurrence within the first year of infection. Prodrome precedes development of lesions. Prodromal symptoms include tingling (paresthesia), itching, and pain where lumbosacral nerves innervate the skin. Prodrome may occur as long as several days or as short as a few hours before lesions develop. Beginning antiviral treatment when prodrome is experienced can reduce the appearance and duration of lesions in some individuals. During recurrence, fewer lesions are likely to develop and are less painful and heal faster (within 5–10 days without antiviral treatment) than those occurring during the primary infection. Subsequent outbreaks tend to be periodic or episodic, occurring on average four or five times a year when not using antiviral therapy.
The causes of reactivation are uncertain, but several potential triggers have been documented. A 2009 study showed the protein VP16 plays a key role in reactivation of the dormant virus. Changes in the immune system during menstruation may play a role in HSV-1 reactivation. Concurrent infections, such as viral upper respiratory tract infection or other febrile diseases, can cause outbreaks. Reactivation due to other infections is the likely source of the historic terms 'cold sore' and 'fever blister'.
The frequency and severity of recurrent outbreaks vary greatly between people. Some individuals' outbreaks can be quite debilitating, with large, painful lesions persisting for several weeks, while others experience only minor itching or burning for a few days. Some evidence indicates genetics play a role in the frequency of cold sore outbreaks. An area of human chromosome 21 that includes six genes has been linked to frequent oral herpes outbreaks. An immunity to the virus is built over time. Most infected individuals experience fewer outbreaks and outbreak symptoms often become less severe. After several years, some people become perpetually asymptomatic and no longer experience outbreaks, though they may still be contagious to others. Immunocompromised individuals may experience longer, more frequent, and more severe episodes. Antiviral medication has been proven to shorten the frequency and duration of outbreaks. Outbreaks may occur at the original site of the infection or in proximity to nerve endings that reach out from the infected ganglia. In the case of a genital infection, sores can appear at the original site of infection or near the base of the spine, the buttocks, or the back of the thighs. HSV-2-infected individuals are at higher risk for acquiring HIV when practicing unprotected sex with HIV-positive persons, in particular during an outbreak with active lesions.
Worldwide rates of either HSV-1 and/or HSV-2 are between 60 and 95% in adults. HSV-1 is more common than HSV-2, with rates of both increasing as people age. HSV-1 rates are between 70% and 80% in populations of low socioeconomic status and 40% to 60% in populations of improved socioeconomic status. An estimated 536 million people or 16% of the population worldwide were infected with HSV-2 as of 2003 with greater rates among women and in those in the developing world. Rates of infection are determined by the presence of antibodies against either viral species.
In the US, 57.7% of the population is infected with HSV-1 and 16.2% are infected with HSV-2. Among those HSV-2-seropositive, only 18.9% were aware they were infected. During 2005–2008, the prevalence of HSV-2 was 39.2% in blacks and 20.9% in women.
Herpes has been known for at least 2,000 years. Emperor Tiberius is said to have banned kissing in Rome for a time due to so many people having cold sores. In the 16th-century Romeo and Juliet, blisters "o'er ladies' lips" are mentioned. In the 18th century, it was so common among prostitutes that it was called "a vocational disease of women". The term 'herpes simplex' appeared in Richard Boulton's A System of Rational and Practical Chirurgery in 1713, where the terms 'herpes miliaris' and 'herpes exedens' also appeared. Herpes was not found to be a virus until the 1940s.
Herpes antiviral therapy began in the early 1960s with the experimental use of medications that interfered with viral replication called deoxyribonucleic acid (DNA) inhibitors. The original use was against normally fatal or debilitating illnesses such as adult encephalitis, keratitis, in immunocompromised (transplant) patients, or disseminated herpes zoster. The original compounds used were 5-iodo-2'-deoxyuridine, AKA idoxuridine, IUdR, or(IDU) and 1-β-D-arabinofuranosylcytosine or ara-C, later marketed under the name cytosar or cytorabine. The usage expanded to include topical treatment of herpes simplex, zoster, and varicella. Some trials combined different antivirals with differing results. The introduction of 9-β-D-arabinofuranosyladenine, (ara-A or vidarabine), considerably less toxic than ara-C, in the mid-1970s, heralded the way for the beginning of regular neonatal antiviral treatment. Vidarabine was the first systemically administered antiviral medication with activity against HSV for which therapeutic efficacy outweighed toxicity for the management of life-threatening HSV disease. Intravenous vidarabine was licensed for use by the U.S. Food and Drug Administration in 1977. Other experimental antivirals of that period included: heparin, trifluorothymidine (TFT), Ribivarin, interferon, Virazole, and 5-methoxymethyl-2'-deoxyuridine (MMUdR). The introduction of 9-(2-hydroxyethoxymethyl)guanine, AKA acyclovir, in the late 1970s raised antiviral treatment another notch and led to vidarabine vs. acyclovir trials in the late 1980s. The lower toxicity and ease of administration over vidarabine has led to acyclovir becoming the drug of choice for herpes treatment after it was licensed by the FDA in 1998. Another advantage in the treatment of neonatal herpes included greater reductions in mortality and morbidity with increased dosages, which did not occur when compared with increased dosages of vidarabine. However, acyclovir seems to inhibit antibody response, and newborns on acyclovir antiviral treatment experienced a slower rise in antibody titer than those on vidarabine.
Society and culture
Herpes simplex was not always stigmatised. It was merely a cold sore in an unusual place until the 1970s. As late as 1975, a study of "Psychological morbidity in a clinic for sexually transmitted disease" does not mention herpes simplex because at that time, no significant morbidity problem (i.e. mental anxiety or illness) was associated with the virus.
Pedro Cuatrecasas states, "during the R&D of acyclovir (Zovirax), marketing [department of Burroughs Wellcome] insisted that there were 'no markets' for this compound. Most had hardly heard of genital herpes..." Thus, marketing the medical condition – separating the 'normal cold sore' from the 'stigmatized genital infection' was to become the key to marketing the drug, a process now known as 'disease mongering'.
Since the creation of the herpes hype, some people experience negative feelings related to the condition following diagnosis, in particular if they have acquired the genital form of the disease. Feelings can include depression, fear of rejection, feelings of isolation, fear of being found out, and self-destructive feelings. These feelings usually lessen over time. Much of the hysteria and stigma surrounding herpes stems from a media campaign beginning in the late 1970s and peaking in the early 1980s. Multiple articles were worded in fear-mongering and anxiety-provoking terminology, such as the now-ubiquitous "attacks", "outbreaks", "victims", and "sufferers". At one point, the term "herpetic" even entered the popular lexicon. The articles were published by Reader's Digest, U.S. News, and Time magazine, among others. A made-for-TV movie was named Intimate Agony. The peak was when Time magazine had 'Herpes: The New Scarlet Letter' on the cover in August 1982, forever stigmatizing the word in the public mind. Herpes support groups have been formed in the United States and the UK, providing information about herpes and running message forums and dating websites for sufferers. People with the herpes virus are often hesitant to divulge to other people, including friends and family, that they are infected. This is especially true of new or potential sexual partners whom they consider casual.
Substantial research has gone into vaccines for both prevention and treatment of herpes infections. Unsuccessful clinical trials have been conducted for glycoprotein subunit vaccines. For therapy, only a single replication-competent HSV vaccine has undergone human testing. As of 2011, the future pipeline includes several promising replication-incompetent vaccine proposals while two replication-competent vaccine proposals require further animal testing.
Researchers at the University of Florida have made a hammerhead ribozyme that targets and cleaves the mRNA of essential genes in HSV-1. The hammerhead, which targets the mRNA of the UL20 gene, greatly reduced the level of HSV-1 ocular infection in rabbits, and reduced the viral yield in vivo. The gene-targeting approach uses a specially designed RNA enzyme to inhibit strains of the herpes simplex virus. The enzyme disables a gene responsible for producing a protein involved in the maturation and release of viral particles in an infected cell. The technique appears to be effective in experiments with mice and rabbits, but further research is required before it can be attempted in people infected with herpes.
Another possibility to eradicate the HSV-1 variant is being pursued by a team at Duke University. By figuring out how to switch all copies of the virus in the host from latency to their active stage at the same time, rather than the way the virus copies normally stagger their activity stage, leaving some dormant somewhere at all times, conventional antiviral drugs might kill the entire virus population, since they can no longer hide in the nerve cells. One class of drugs called antagomir could serve this purpose. These are chemically engineered oligonucleotides or short segments of RNA that can be made to mirror their target genetic material, namely herpes microRNAs. They could be engineered to attach and thus 'silence' the microRNA, thus rendering the virus incapable of remaining latent in its host. Professor Cullen believes a drug could be developed to block the microRNA whose job it is to suppress HSV-1 into latency.
- "Genital Herpes - CDC Fact Sheet". cdc.gov. December 8, 2014. Retrieved 31 December 2014.
- Balasubramaniam, R; Kuperstein, AS; Stoopler, ET (April 2014). "Update on oral herpes virus infections.". Dental clinics of North America 58 (2): 265–80. doi:10.1016/j.cden.2013.12.001. PMID 24655522.
- Mosby (2013). Mosby's Medical Dictionary (9 ed.). Elsevier Health Sciences. pp. 836–837. ISBN 9780323112581.
- Wu, IB; Schwartz, RA (March 2007). "Herpetic whitlow.". Cutis 79 (3): 193–6. PMID 17674583.
- Rowe, AM; St Leger, AJ; Jeon, S; Dhaliwal, DK; Knickelbein, JE; Hendricks, RL (January 2013). "Herpes keratitis.". Progress in retinal and eye research 32: 88–101. doi:10.1016/j.preteyeres.2012.08.002. PMID 22944008.
- Steiner, I; Benninger, F (December 2013). "Update on herpes virus infections of the nervous system.". Current neurology and neuroscience reports 13 (12): 414. doi:10.1007/s11910-013-0414-8. PMID 24142852.
- Stephenson-Famy, A; Gardella, C (December 2014). "Herpes Simplex Virus Infection During Pregnancy.". Obstetrics and gynecology clinics of North America 41 (4): 601–614. doi:10.1016/j.ogc.2014.08.006. PMID 25454993.
- Elad S, Zadik Y, Hewson I et al. (August 2010). "A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea". Support Care Cancer 18 (8): 993–1006. doi:10.1007/s00520-010-0900-3. PMID 20544224.
- Chayavichitsilp P, Buckwalter JV, Krakowski AC, Friedlander SF (April 2009). "Herpes simplex". Pediatr Rev 30 (4): 119–29; quiz 130. doi:10.1542/pir.30-4-119. PMID 19339385.
- Looker, KJ; Garnett, GP; Schmid, GP (October 2008). "An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection.". Bulletin of the World Health Organization 86 (10): 805–12, A. doi:10.2471/blt.07.046128. PMC 2649511. PMID 18949218.
- Dickerson FB, Boronow JJ, Stallings C et al. (March 2004). "Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder". Biol. Psychiatry 55 (6): 588–93. doi:10.1016/j.biopsych.2003.10.008. PMID 15013827.
- Gupta R, Warren T, Wald A (December 2007). "Genital herpes". Lancet 370 (9605): 2127–37. doi:10.1016/S0140-6736(07)61908-4. PMID 18156035.
- Handsfield HH (2000). "Public Health Strategies to Prevent Genital Herpes: Where Do We Stand?". Curr Infect Dis Rep 2 (1): 25–30. doi:10.1007/s11908-000-0084-y. PMID 11095834.
- Herpes Encephalitis at eMedicine
- Jocelyn A. Lieb, Stacey Brisman, Sara Herman, Jennifer MacGregor, Marc E. Grossman (2008). "Linear erosive Herpes Simplex Virus infection in immunocompromised patients: the "Knife-Cut Sign"". Clin Infect Dis 47 (11): 1440–1. doi:10.1086/592976. PMID 18937574.
- James, William D.; Berger, Timothy G. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
- Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 1-4160-2999-0.
- Tankéré F, Bernat I (September 2009). "[Bell's palsy: from viral aetiology to diagnostic reality]". Rev Med Interne (in French) 30 (9): 769–75. doi:10.1016/j.revmed.2008.12.006. PMID 19195745.
- Linder T, Bossart W, Bodmer D (January 2005). "Bell's palsy and Herpes simplex virus: fact or mystery?". Otol. Neurotol. 26 (1): 109–13. doi:10.1097/00129492-200501000-00020. PMID 15699730.
- Lockhart P, Daly F, Pitkethly M, Comerford N, Sullivan F (2009). Lockhart, Pauline, ed. "Antiviral treatment for Bell's palsy (idiopathic facial paralysis)". Cochrane Database Syst Rev (4): CD001869. doi:10.1002/14651858.CD001869.pub4. PMID 19821283.
- Itzhaki RF, Wozniak MA (May 2008). "Herpes simplex virus type 1 in Alzheimer's disease: the enemy within". J. Alzheimers Dis. 13 (4): 393–405. PMID 18487848.
- Holmes C, Cotterell D (December 2009). "Role of infection in the pathogenesis of Alzheimer's disease: implications for treatment". CNS Drugs 23 (12): 993–1002. doi:10.2165/11310910-000000000-00000. PMID 19958038.
- Dobson CB, Itzhaki RF (1999). "Herpes simplex virus type 1 and Alzheimer's disease". Neurobiol. Aging 20 (4): 457–65. doi:10.1016/S0197-4580(99)00055-X. PMID 10604441.
- Pyles RB (2001). "The association of herpes simplex virus and Alzheimer's disease: a potential synthesis of genetic and environmental factors". Herpes 8 (3): 64–8. PMID 11867022.
- Warren, Terri (2009). The Good News about the Bad News: Herpes: Everything You Need to Know. New Harbinger Publications. p. 28. ISBN 1-57224-618-9.
- "AHMF: Preventing Sexual Transmission of Genital herpes". Archived from the original on January 21, 2008. Retrieved 2008-02-24.
- Wysocki, edited by Anita L. Nelson, JoAnn Woodward ; foreword by Susan (2006). Sexually transmitted diseases : a practical guide for primary care. Totowa, N.J.: Totowa, N.J. p. 50. ISBN 978-1-58829-570-5.
- Leone P (2005). "Reducing the risk of transmitting genital herpes: advances in understanding and therapy". Curr Med Res Opin 21 (10): 1577–82. doi:10.1185/030079905X61901. PMID 16238897.
- Akhtar, Jihan; Shukla, Deepak (December 2009). "Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry". FEBS Journal 276 (24): 7228–36. doi:10.1111/j.1742-4658.2009.07402.x. PMC 2801626. PMID 19878306.
- Shukla, Deepak; Liu, Jian; Blaiklock, Peter; Shworak, Nicholas W.; Bai, Xiaomei; Esko, Jeffrey D.; Cohen, Gary H.; Eisenberg, Roselyn et al. (1999). "A Novel Role for 3-O-Sulfated Heparan Sulfate in Herpes Simplex Virus 1 Entry". Cell 99 (1): 13–22. doi:10.1016/S0092-8674(00)80058-6. PMID 10520990.
- Kim H, Meier A, Huang M, Kuntz S, Selke S, Celum C, Corey L, Wald A (2006). "Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men". J Infect Dis 194 (4): 420–7. doi:10.1086/505879. PMID 16845624.
- Mertz, G.J. (1993). "Epidemiology of genital herpes infections". Infect Dis Clin North Am 7 (4): 825–39. PMID 8106731.
- Fatahzadeh M, Schwartz RA (2007). "Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management". J. Am. Acad. Dermatol. 57 (5): 737–63; quiz 764–6. doi:10.1016/j.jaad.2007.06.027. PMID 17939933.
- Ashley RL et al. (1988). "Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera". J. Clin. Microbiol. 26 (4): 662–7. PMC 266403. PMID 2835389.
- Warren, Terri (2009). The Good News About The Bad News. New Harbinger Publications. p. 209. ISBN 1-57224-618-9.
- Carla K. Johnson (August 23, 2006). "Percentage of people with herpes drops". Associated Press. Archived from the original on 2012-03-08. Retrieved 2011-04-12.
- Kulhanjian JA, Soroush V, Au DS et al. (April 2, 1992). "Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy". N. Engl. J. Med. 326 (14): 916–20. doi:10.1056/NEJM199204023261403. PMID 1311799.
- Corey L, Wald A, Patel R et al. (January 2004). "Once-daily valacyclovir to reduce the risk of transmission of genital herpes" (PDF). N Engl J Med. 350 (1): 11–20. doi:10.1056/NEJMoa035144. PMID 14702423.
- Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, Tyring S, Douglas JM Jr, Corey L. (2001). "Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women". JAMA 285 (24): 3100–6. doi:10.1001/jama.285.24.3100. PMID 11427138.
- Wald A, Langenberg AG, Krantz E et al. (November 2005). "The relationship between condom use and herpes simplex virus acquisition". Annals of Internal Medicine 143 (10): 707–13. doi:10.7326/0003-4819-143-10-200511150-00007. PMID 16287791.
- Mertz, GJ; Benedetti J; Ashley R; Selke SA; Corey L. (1 February 1992). "Risk factors for the sexual transmission of genital herpes". Annals of Internal Medicine 116 (3): 197–202. doi:10.7326/0003-4819-116-3-197. PMID 1309413.
- "Genital Herpes - CDC Fact Sheet". Center for Disease Control and Prevention. Retrieved 2014-01-30.
- McNeil DJ. http://www.nytimes.com/2011/10/21/health/research/21herpes.htmlTopical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication. NY Times. Research article: Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication.
- Emily T. Martin, MPH; Elizabeth Krantz, MS; Sami L. Gottlieb, MD, MSPH; Amalia S. Magaret, PhD; Andria Langenberg, MD; Lawrence Stanberry, MD, PhD; Mary Kamb, MD, MPH; Anna Wald, MD, MPH (2009). "A Pooled Analysis of the Effect of Condoms in Preventing HSV-2 Acquisition". Archives of Internal Medicine 169 (13): 1233–40. doi:10.1001/archinternmed.2009.177. PMC 2860381. PMID 19597073.
- "Putting Herpes in Perspective". UBM Medica. Retrieved 20 July 2011.
- "Condom Effectiveness – Male Latex Condoms and Sexually Transmitted Diseases". Center for Disease Control and Prevention. Retrieved October 2011.
- "STD Facts – Genital Herpes". Center for Disease Control and Prevention. Retrieved October 2011.
- Koelle, D.M.; Wald, A. (April 2000). "Herpes simplex virus: The importance of asymptomatic shedding". J. Antimicrob. Chemother. 45 (Suppl T3): 1–8. doi:10.1093/jac/45.suppl_4.1. PMID 10855766.
- Brown ZA, Selke S, Zeh J et al. (1997). "The acquisition of herpes simplex virus during pregnancy". N Engl J Med 337 (8): 509–515. doi:10.1056/NEJM199708213370801. PMID 9262493.
- Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L (2003). "Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant". JAMA 289 (2): 203–9. doi:10.1001/jama.289.2.203. PMID 12517231.
- Brown ZA, Benedetti J, Ashley R et al. (May 1991). "Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor". N. Engl. J. Med. 324 (18): 1247–52. doi:10.1056/NEJM199105023241804. PMID 1849612.
- Whitley RJ, Kimberlin DW, Roizman B (1998). "Herpes simplex viruses". Clin Infect Dis 26 (3): 541–53. doi:10.1086/514600. PMID 9524821.
- O'Mahony C, Timms MS, Ramsden RT (December 1988). "Local anesthetic creams". BMJ 297 (6661): 1468. doi:10.1136/bmj.297.6661.1468-a. PMC 1835116. PMID 3147021.
- Kaminester LH, Pariser RJ, Pariser DM et al. (December 1999). "A double-blind, placebo-controlled study of topical tetracaine in the treatment of herpes labialis". J. Am. Acad. Dermatol. 41 (6): 996–1001. doi:10.1016/S0190-9622(99)70260-4. PMID 10570387.
- Leung DT, Sacks SL (October 2003). "Current treatment options to prevent perinatal transmission of herpes simplex virus". Expert Opin Pharmacother 4 (10): 1809–19. doi:10.1517/146565220.127.116.119. PMID 14521490.
- LaFemina, edited by Robert L. (2009). Antiviral research : strategies in antiviral drug discovery. Washington, DC: ASM Press. p. 1. ISBN 978-1-55581-439-7.
- Agrawal, Caroline A. Hastings, Joseph Torkildson, Anurag Kishor. Handbook of pediatric hematology and oncology : Children's Hospital & Research Center Oakland (2nd ed.). Chichester, West Sussex: Wiley-Blackwell. p. 360. ISBN 978-0-470-67088-0.
- Chon T, Nguyen L, Elliott TC (July 2007). "Clinical inquiries. What are the best treatments for herpes labialis?". J Fam Pract 56 (7): 576–8. PMID 17605952.
- Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T (2009). Glenny, Anne-Marie, ed. "Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer". Cochrane Database Syst Rev (1): CD006706. doi:10.1002/14651858.CD006706.pub2. PMID 19160295.
- Nasser M, Fedorowicz Z, Khoshnevisan MH, Shahiri Tabarestani M (2008). Nasser, Mona, ed. "Acyclovir for treating primary herpetic gingivostomatitis". Cochrane Database Syst Rev (4): CD006700. doi:10.1002/14651858.CD006700.pub2. PMID 18843726.
- Treister NS, Woo SB (April 2010). "Topical n-docosanol for management of recurrent herpes labialis". Expert Opin Pharmacother 11 (5): 853–60. doi:10.1517/14656561003691847. PMID 20210688.
- Reviewed by EBSCO CAM Review Board in July 2012. "Herpes". HERPES: Principal Proposed Natural Treatments | Other Proposed Natural Treatments. EBSCO. Retrieved 11 May 2013.
- Perfect MM, Bourne N, Ebel C, Rosenthal SL (October 2005). "Use of complementary and alternative medicine for the treatment of genital herpes". Herpes 12 (2): 38–41. PMID 16209859.
- Beauman, JG (Oct 15, 2005). "Genital herpes: a review.". American family physician 72 (8): 1527–34. PMID 16273819.
- Stumpf MP, Laidlaw Z, Jansen VA (2002). "Herpes viruses hedge their bets". Proc. Natl. Acad. Sci. U.S.A. 99 (23): 15234–7. doi:10.1073/pnas.232546899. PMC 137573. PMID 12409612.
- "How Herpes Re-rears Its Ugly Head". Science News.
- Myśliwska J, Trzonkowski P, Bryl E, Lukaszuk K, Myśliwski A (2000). "Lower interleukin-2 and higher serum tumor necrosis factor-a levels are associated with perimenstrual, recurrent, facial herpes simplex infection in young women". Eur. Cytokine Netw. 11 (3): 397–406. PMID 11022124.
- Segal AL, Katcher AH, Brightman VJ, Miller MF (1974). "Recurrent herpes labialis, recurrent aphthous ulcers, and the menstrual cycle". J. Dent. Res. 53 (4): 797–803. doi:10.1177/00220345740530040501. PMID 4526372.
- Chambers A, Perry M (2008). "Salivary mediated autoinoculation of herpes simplex virus on the face in the absence of "cold sores," after trauma". J. Oral Maxillofac. Surg. 66 (1): 136–8. doi:10.1016/j.joms.2006.07.019. PMID 18083428.
- Perna JJ, Mannix ML, Rooney JF, Notkins AL, Straus SE (1987). "Reactivation of latent herpes simplex virus infection by ultraviolet light: a human model". J. Am. Acad. Dermatol. 17 (3): 473–8. doi:10.1016/S0190-9622(87)70232-1. PMID 2821086.
- Rooney JF, Straus SE, Mannix ML et al. (1992). "UV light-induced reactivation of herpes simplex virus type 2 and prevention by acyclovir". J. Infect. Dis. 166 (3): 500–6. doi:10.1093/infdis/166.3.500. PMID 1323616.
- Oakley C, Epstein JB, Sherlock CH (1997). "Reactivation of oral herpes simplex virus: implications for clinical management of herpes simplex virus recurrence during radiotherapy". Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84 (3): 272–8. doi:10.1016/S1079-2104(97)90342-5. PMID 9377190.
- Ichihashi M, Nagai H, Matsunaga K (2004). "Sunlight is an important causative factor of recurrent herpes simplex". Cutis 74 (5 Suppl): 14–8. PMID 15603217.
- Martinez V, Caumes E, Chosidow O (2008). "Treatment to prevent recurrent genital herpes". Current Opinion in Infectious Diseases 21 (1): 42–48. doi:10.1097/QCO.0b013e3282f3d9d3. PMID 18192785.
- Koelle DM, Corey L (2008). "Herpes Simplex: Insights on Pathogenesis and Possible Vaccines". Annu Rev Med 59: 381–395. doi:10.1146/annurev.med.59.061606.095540. PMID 18186706.
- Smith JS, Robinson NJ (2002). "Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review". J. Infect. Dis. 186 (Suppl 1): S3–28. doi:10.1086/343739. PMID 12353183.
- Xu, Fujie; Fujie Xu, MD, PhD; Maya R. Sternberg, PhD; Benny J. Kottiri, PhD; Geraldine M. McQuillan, PhD; Francis K. Lee, PhD; Andre J. Nahmias, MD; Stuart M. Berman, MD, ScM; Lauri E. Markowitz, MD (2006-10-23). "Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States". JAMA (AMA) 296 (8): 964–73. doi:10.1001/jama.296.8.964. PMID 16926356.
- Xu, F; MR Sternberg, PhD, SL Gottlieb, MD, SM Berman, MD, LE Markowitz, MD, Div of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; SE Forhan, MD, LD Taylor, DrPH, EIS officers, CDC (23 April 2010). "Seroprevalence of Herpes Simplex Virus Type 2 Among Persons Aged 14—49 Years — United States, 2005—2008". Morbidity and Mortality Weekly Report (MMWR) 59 (15): 456–9. Retrieved 12 April 2011.
- "CDC Study Finds U.S. Herpes Rates Remain High". Center for Disease Control and Prevention. 2010-03-09. Retrieved 2012-02-19.
- John Leo (1982-08-02). "The New Scarlet Letter". Time.
- Chow AW, Roland A, Fiala M et al. (March 1973). "Cytosine Arabinoside Therapy for Herpes Simplex Encephalitis—Clinical Experience with Six Patients". Antimicrob. Agents Chemother. 3 (3): 412–7. doi:10.1128/aac.3.3.412. PMC 444424. PMID 4790599.
- Kaufman HE, Howard GM (August 1962). "Therapy of experimental herpes simplex keratitis". Invest Ophthalmol 1: 561–4. PMID 14454441.
- Ch'ien LT, Whitley RJ, Alford CA, Galasso GJ (June 1976). "Adenine arabinoside for therapy of herpes zoster in immunosuppressed patients: preliminary results of a collaborative study". J. Infect. Dis. 133 (Suppl): A184–91. doi:10.1093/infdis/133.supplement_2.a184. PMID 180198.
- McKelvey EM, Kwaan HC (November 1969). "Cytosine arabinoside therapy for disseminated herpes zoster in a patient with IgG pyroglobulinemia". Blood 34 (5): 706–11. PMID 5352659.
- Fiala M, Chow A, Guze LB (April 1972). "Susceptibility of Herpesviruses to Cytosine Arabinoside: Standardization of Susceptibility Test Procedure and Relative Resistance of Herpes Simplex Type 2 Strains". Antimicrob. Agents Chemother. 1 (4): 354–7. doi:10.1128/aac.1.4.354. PMC 444221. PMID 4364937.
- Allen LB, Hintz OJ, Wolf SM et al. (June 1976). "Effect of 9-beta-D-arabinofuranosylhypoxanthine 5'-monophosphate on genital lesions and encephalitis induced by Herpesvirus hominis type 2 in female mice". J. Infect. Dis. 133 (Suppl): A178–83. doi:10.1093/infdis/133.supplement_2.a178. PMID 6598.
- Juel-Jensen BE (March 1970). "Varicella and cytosine arabinoside". Lancet 1 (7646): 572. doi:10.1016/S0140-6736(70)90815-9. PMID 4190397.
- Nahmias AJ, Kibrick S (May 1964). "Inhibitory Effect of Heparin on Herpes Simplex Virus". J. Bacteriol. 87 (5): 1060–6. PMC 277146. PMID 4289440.
- Allen LB, Sidwell RW (September 1972). "Target-Organ Treatment of Neurotropic Virus Diseases: Efficacy as a Chemotherapy Tool and Comparison of Activity of Adenine Arabinoside, Cytosine Arabinoside, Idoxuridine, and Trifluorothymidine". Antimicrob. Agents Chemother. 2 (3): 229–33. doi:10.1128/aac.2.3.229. PMC 444296. PMID 4790562.
- Allen LB, Wolf SM, Hintz CJ, Huffman JH, Sidwell RW (March 1977). "Effect of ribavirin on Type 2 Herpesvirus hominis (HVH/2) in vitro and in vivo". Annals of the New York Academy of Sciences 284: 247–53. doi:10.1111/j.1749-6632.1977.tb21957.x. PMID 212976.
- Allen LB, Cochran KW (November 1972). "Target-Organ Treatment of Neurotropic Virus Disease with Interferon Inducers". Infection and Immunity 6 (5): 819–23. PMC 422616. PMID 4404669.
- Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK (August 1972). "Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide". Science 177 (4050): 705–6. doi:10.1126/science.177.4050.705. PMID 4340949.
- Babiuk LA, Meldrum B, Gupta VS, Rouse BT (December 1975). "Comparison of the Antiviral Effects of 5-Methoxymethyl-deoxyuridine with 5-Iododeoxyuridine, Cytosine Arabinoside, and Adenine Arabinoside". Antimicrob. Agents Chemother. 8 (6): 643–50. doi:10.1128/aac.8.6.643. PMC 429441. PMID 1239978.
- O'Meara A, Deasy PF, Hillary IB, Bridgen WD (December 1979). "Acyclovir for treatment of mucocutaneous herpes infection in a child with leukaemia". Lancet 2 (8153): 1196. doi:10.1016/S0140-6736(79)92428-0. PMID 91931.
- Whitley R, Arvin A, Prober C et al. (February 1991). "A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group". N. Engl. J. Med. 324 (7): 444–9. doi:10.1056/NEJM199102143240703. PMID 1988829.
- Kimberlin DW, Lin CY, Jacobs RF et al. (August 2001). "Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections". Pediatrics 108 (2): 230–8. doi:10.1542/peds.108.2.230. PMID 11483782.
- Mayou, R (1975). "Psychological morbidity in a clinic for sexually transmitted disease". The British journal of venereal diseases 51 (1): 57–60. doi:10.1136/sti.51.1.57. PMC 1045113. PMID 1173225.
- Moynihan R, Heath I, Henry D (April 2002). "Selling sickness: the pharmaceutical industry and disease mongering". BMJ 324 (7342): 886–91. doi:10.1136/bmj.324.7342.886. PMC 1122833. PMID 11950740.
- Cuatrecasas P (November 2006). "Drug discovery in jeopardy". J. Clin. Invest. 116 (11): 2837–42. doi:10.1172/JCI29999. PMC 1626142. PMID 17080187.
- Vezina C, Steben M. (2001). "Genital Herpes: Psychosexual Impacts and Counselling" (PDF). The Canadian Journal of CME (June): 125–34.
- Green, J; Ferrier, S; Kocsis, A; Shadrick, J; Ukoumunne, OC; Murphy, S; Hetherton, J (February 2003). "Determinants of disclosure of genital herpes to partners.". Sexually transmitted infections 79 (1): 42–4. doi:10.1136/sti.79.1.42. PMC 1744583. PMID 12576613.
- Johnston C, Koelle DM, Wald A (Dec 2011). "HSV-2: in pursuit of a vaccine.". J Clin Invest 121 (12): 4600–9. doi:10.1172/JCI57148. PMID 22133885.
- Liu J, Tuli SS, Bloom DC, Schultz GS, Ghivizzani SC, Lewin AS (2006). "801. RNA Gene Therapy Targeting Herpes Simplex Virus". Molecular Therapy 13: S310. doi:10.1016/j.ymthe.2006.08.890.
- "Potential new herpes therapy studied". University of Florida News. 2009-02-03. Retrieved 2011-04-12.
- Fox, Maggie (2008-07-02). "New approach offers chance to finally kill herpes". Reuters. Retrieved 2011-04-12.
- Kingsbury, Kathleen (2008-07-02). "A Cure for Cold Sores?". Time. Retrieved 2010-05-04.
- Foley, James A. (21 Oct 2013). "Hitchhiking Herpes Virus Aligns with Spread of Human Civilization". NatureWorldNews.com. Retrieved 22 October 2013.
|Wikimedia Commons has media related to Herpesviridae.|